Anixa Biosciences (ANIX) Total Non-Current Liabilities (2013 - 2017)
Anixa Biosciences' (ANIX) quarterly Total Non-Current Liabilities came in at $3.7 million in Q1 2017, up 199.35% YoY from $1.2 million in Q1 2016, and up 694.43% on a QoQ basis from $468756.0 in Q4 2016.
Anixa Biosciences (ANIX) Total Non-Current Liabilities (2013 - 2017) Analysis & Trends
Anixa Biosciences (ANIX) has 5 years of Total Non-Current Liabilities data on file, last reported at $3.7 million in Q1 2017.
- Quarterly Total Non-Current Liabilities rose 199.35% year-over-year to $3.7 million in Q1 2017, while the trailing twelve-month figure through Jan 2017 was $3.7 million (up 199.35% YoY) and the FY2016 annual result came in at $468756.0, down 21.06% from the prior year.
- Total Non-Current Liabilities improved to $3.7 million in Q1 2017, from $468756.0 in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $10.0 million in Q3 2014 to a low of $468756.0 in Q4 2016.
- A 5-year average of $3.5 million and a median of $1.7 million in 2014 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2015 — Total Non-Current Liabilities plunged 92.89% — and 2017, when it soared 199.35%.
- Tracing ANIX's Total Non-Current Liabilities over 5 years: stood at $8.2 million in 2013, then tumbled by 77.99% to $1.8 million in 2014, then sank by 67.19% to $593782.0 in 2015, then dropped by 21.06% to $468756.0 in 2016, then surged by 694.43% to $3.7 million in 2017.
- The last three Total Non-Current Liabilities figures came in at $3.7 million (Q1 2017), $468756.0 (Q4 2016), and $531624.0 (Q3 2016), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.17 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.32 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 724.15 Mn |
| 10 | Anixa Biosciences | 121.44 Mn | 121.44 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jan 31, 2017 | 3.72 Mn |
| Oct 31, 2016 | 468,756.00 |
| Jul 31, 2016 | 531,624.00 |
| Apr 30, 2016 | 706,930.00 |
| Jan 31, 2016 | 1.24 Mn |
| Oct 31, 2015 | 593,782.00 |
| Jul 31, 2015 | 711,666.00 |
| Apr 30, 2015 | 688,676.00 |
| Jan 31, 2015 | 1.67 Mn |
| Oct 31, 2014 | 1.81 Mn |
| Jul 31, 2014 | 10.01 Mn |
| Apr 30, 2014 | 7.46 Mn |
| Jan 31, 2014 | 6.90 Mn |
| Oct 31, 2013 | 8.22 Mn |
| Jul 31, 2013 | 4.61 Mn |
| Apr 30, 2013 | 7.31 Mn |